Last reviewed · How we verify

Surfen (AMINOQUINURIDE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Surfen (generic name: AMINOQUINURIDE) is a aminoquinuride drug. It is currently in Phase 2 development.

Surfen works by blocking the action of an enzyme called interstitial collagenase, which breaks down collagen.

Surfen is a small molecule with the synonyms AMINOCHINURIDE, AMINOQUINURIDA, and AMINOQUINURIDE. It has been studied in clinical trials for the treatment of hemorrhoids, anal pain, and stings, using topical vitamin E ovules and prednisolone ointment as interventions.

Likelihood of approval
12.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • CNS / neurology attrition -3.0pp
    CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAMINOQUINURIDE
Drug classaminoquinuride
TargetMatrix metalloproteinase-9, Interstitial collagenase, Botulinum neurotoxin type A
ModalitySmall molecule
Therapeutic areaNeuroscience
PhasePhase 2

Mechanism of action

Think of collagen like a strong rope that holds things together. When interstitial collagenase is active, it can break down this rope, leading to damage and disease. Surfen helps to stop this breakdown by blocking the action of the enzyme, which can help to prevent or treat conditions where collagen is damaged.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Surfen

What is Surfen?

Surfen (AMINOQUINURIDE) is a aminoquinuride drug.

How does Surfen work?

Surfen works by blocking the action of an enzyme called interstitial collagenase, which breaks down collagen.

What is the generic name of Surfen?

AMINOQUINURIDE is the generic (nonproprietary) name of Surfen.

What drug class is Surfen in?

Surfen belongs to the aminoquinuride class. See all aminoquinuride drugs at /class/aminoquinuride.

What development phase is Surfen in?

Surfen is in Phase 2.

What does Surfen target?

Surfen targets Matrix metalloproteinase-9, Interstitial collagenase, Botulinum neurotoxin type A and is a aminoquinuride.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing